Enozertinib vs Neratinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR/HER2 · full Non-Small Cell Lung Cancer pipeline
Enozertinib
Developed by ORIC Pharmaceuticals under a licence from Voronoi, Inc
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06816992 (registry estimate)
No aligned efficacy figure on record for this race.
Neratinib
Marketed by Puma Biotechnology and partners
NCT01827267 · Phase 2 · completed
Patients were randomized between neratinib alone and neratinib plus temsirolimus, but the trial was open-label (unblinded) and each arm was small; the response-rate difference (0% vs 14%) was not accompanied by a reported statistical test, so whether adding temsirolimus produced a real benefit is unclear.
Reported efficacy
Objective Response Rate for Neratinib in Patients With Non-small Cell Lung Cancer (From first dose date to progression/death or last tumor assessment, up to three years.): Objective response rate (primary endpoint): 3% in arm A (prior TKI, EGFR-mutation positive, n=91), 0% in arm B (prior TKI, EGFR wild-type, n=48), 0% in arm C (TKI-naive, n=28); 3 of 4 patients with exon 18 G719X EGFR mutation had a partial response (missed)
Result source: NCT00266877
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Enozertinib | Neratinib |
|---|---|---|
| PFS, median | —Not reported | 2.9bNCT018272674 other results
|
| OS, median | —Not reported | 10bNCT018272671 other result
|
| ORR | —Not reported | 3.3%bNCT002668772 other results
|
| Duration of response, median | —Not reported | 12.5bNCT002668771 other result
|
PFS, median
- Enozertinib
- —Not reported
- Neratinib
- 2.9bNCT01827267
4 other results
- 4 NCT01827267
- 3.5 NCT00266877
- 3.7 NCT00266877
- 2.1 NCT00266877
OS, median
- Enozertinib
- —Not reported
- Neratinib
- 10bNCT01827267
1 other result
- 15.1 NCT01827267
ORR
- Enozertinib
- —Not reported
- Neratinib
- 3.3%bNCT00266877
2 other results
- 0% NCT00266877
- 3.6% NCT00266877
Duration of response, median
- Enozertinib
- —Not reported
- Neratinib
- 12.5bNCT00266877
1 other result
- 6.6 NCT00266877
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Enozertinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Enozertinib: 0 of 4 rows · Neratinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Neratinib |
|---|---|
| Dropout rate | 27.8%Neratiniba NCT01827267 · Phase 2 show 4 more results27.3%Neratinib+Temsirolimus NCT01827267 · Phase 2 · combination n/a: no completion milestoneNo Prior EGFR Tyrosine Kinase Inhi NCT00266877 · Phase 2 n/a: no completion milestonePrior Tarceva or Iressa With EGFR NCT00266877 · Phase 2 n/a: no completion milestonePrior Tarceva or Iressa w/o EGFR M NCT00266877 · Phase 2 |
| Discontinued due to AEs | —Neratiniba NCT01827267 · Phase 2 show 4 more results—Neratinib+Temsirolimus NCT01827267 · Phase 2 · combination 3.6%No Prior EGFR Tyrosine Kinase Inhi NCT00266877 · Phase 2 6.6%Prior Tarceva or Iressa With EGFR NCT00266877 · Phase 2 8.3%Prior Tarceva or Iressa w/o EGFR M NCT00266877 · Phase 2 |
| Serious AEs | 41.2%Neratiniba NCT01827267 · Phase 2 show 4 more results37.2%Neratinib+Temsirolimus NCT01827267 · Phase 2 · combination 50%No Prior EGFR Tyrosine Kinase Inhi NCT00266877 · Phase 2 36.3%Prior Tarceva or Iressa With EGFR NCT00266877 · Phase 2 43.8%Prior Tarceva or Iressa w/o EGFR M NCT00266877 · Phase 2 |
| Most frequent reported AEs | show 4 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Neratinib
show 1 more result
show 1 more result
show 4 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enozertinib's landscape · Neratinib's landscape